United Therapeutics Corporation
United Therapeutics Announces 20% Year-over-Year Revenue Growth for Q2 2024
Summary
United Therapeutics Corporation reported a 20% year-over-year increase in total revenues for the second quarter of 2024, reaching $714.9 million. Net income also grew by 7% to $278.1 million. The growth was driven by increased sales of Tyvaso, Remodulin, Orenitram, and Unituxin, partially offset by a decline in Adcirca sales. The company also announced an accelerated share repurchase agreement with Citibank, N.A., under which it repurchased shares worth $1.0 billion in March 2024.
Profitelligence Alerts
Get alerts for UTHR
Be first to know when United Therapeutics Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.
Official SEC Documents
Advertisement